In this week’s video, Dr. Brian G.M. Durie explains the recent FDA approval for the use of elotuzumab, pomalidomide, and dexamethasone (EPd) for the treatment of relapsed or refractory myeloma in patients who have received at least two prior therapies.

BOTTOM LINE:
An important new combination – EPd – is now approved and available.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
How important is the FDA approval of once-weekly dosage of Kyprolis (carfilzomib) for multiple myeloma patients?
Next Post
iStopMM Is Leading the Way to a Cure and Is Honored at a Presidential Luncheon

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.